Structural and Functional Diversity of Animal Toxins Interacting With GPCRs

Abstract

Peptide toxins from venoms have undergone a long evolutionary process allowing host defense or prey capture and making them highly selective and potent for their target. This has resulted in the emergence of a large panel of toxins from a wide diversity of species, with varied structures and multiple associated biological functions. In this way, animal toxins constitute an inexhaustible reservoir of druggable molecules due to their interesting pharmacological properties. One of the most interesting classes of therapeutic targets is the G-protein coupled receptors (GPCRs). GPCRs represent the largest family of membrane receptors in mammals with approximately 800 different members. They are involved in almost all biological functions and are the target of almost 30% of drugs currently on the market. Given the interest of GPCRs in the therapeutic field, the study of toxins that can interact with and modulate their activity with the purpose of drug development is of particular importance. The present review focuses on toxins targeting GPCRs, including peptide-interacting receptors or aminergic receptors, with a particular focus on structural aspects and, when relevant, on potential medical applications. The toxins described here exhibit a great diversity in size, from 10 to 80 amino acids long, in disulfide bridges, from none to five, and belong to a large panel of structural scaffolds. Particular toxin structures developed here include inhibitory cystine knot (ICK), three-finger fold, and Kunitz-type toxins. We summarize current knowledge on the structural and functional diversity of toxins interacting with GPCRs, concerning first the agonist-mimicking toxins that act as endogenous agonists targeting the corresponding receptor, and second the toxins that differ structurally from natural agonists and which display agonist, antagonist, or allosteric properties.

Natural Peptide Toxins as an Option for Renewed Treatment of Type 2 Vasopressin Receptor-Related Diseases

“…Toxins are largely known for their activities in ionic channels and the cardiovascular system, which have been reviewed for conus [ 55 ], snake [ 56 ], scorpion [ 57 ], spider [ 58 ], centipede [ 59 ] and sea anemone [ 60 ]. An increasing number of animal toxins have also been described to be active in GPCRs, with an interesting classification: agonist-mimicking toxins and non-related agonist toxins, as recently reviewed in [ 61 ]. Here, both families of toxins active on the V2R are detailed.…”

Nanobiotechnology with Therapeutically Relevant Macromolecules from Animal Venoms: Venoms, Toxins, and Antimicrobial Peptides

“…It is incontestable that peptides from animal venoms have therapeutic potential [ 153 ]. According to Van Baelen et al [ 154 ], there are about 200,000 species of venomous animals around the world with about 40 million toxins to be exploited. However, there are only 11 peptide rugs derived from animal venom on the market, tens are in clinical development, and hundreds of patents have been filed in this field [ 155 ].…”

Isomeric Activity Cliffs—A Case Study for Fluorine Substitution of Aminergic G Protein-Coupled Receptor Ligands

“…G protein-coupled receptors (GPCRs) constitute a significant group of membrane-bound receptors that contain five different classes [ 1 ] and represent more than 30% of therapeutic targets [ 2 ]. The aminergic subfamily of receptors is present in class A and includes receptors for acetylcholine, dopamine, epinephrine, histamine, serotonin, and trace amine [ 1 ].…”